Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).
The experts:
Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Prof. Agnieszka Wierzbowska, Medical University of Lodz, Poland
Prof. Gert Ossenkoppele, Vrije Universiteit University Medical Center, Amsterdam, Netherlands
This touchPODCAST is for HCPs only…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.